Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
-
- Timothy P. Hughes
- South Australian Health and Medical Research Institute, University of Adelaide, Adelaide, SA, Australia;
-
- Giuseppe Saglio
- University of Turin, Orbassano, Italy;
-
- Hagop M. Kantarjian
- The University of Texas MD Anderson Cancer Center, Houston, TX;
-
- François Guilhot
- Institut National de la Santé et de la Recherche Médicale Centre d'Investigation Clinique 0802, Centre Hospitalier Universitaire de Poitiers, Poitiers, France;
-
- Dietger Niederwieser
- University of Leipzig, Leipzig, Saxony, Germany;
-
- Gianantonio Rosti
- University of Bologna, Bologna, Italy;
-
- Chiaki Nakaseko
- Chiba University Hospital, Chiba, Japan;
-
- Carmino Antonio De Souza
- University of Campinas, Campinas, Brazil;
-
- Matt E. Kalaycio
- Cleveland Clinic, Cleveland, OH;
-
- Stephan Meier
- Novartis Pharma AG, Basel, Switzerland;
-
- Xiaolin Fan
- Novartis Pharmaceuticals Corporation, East Hanover, NJ;
-
- Hans D. Menssen
- Novartis Pharma AG, Basel, Switzerland;
-
- Richard A. Larson
- University of Chicago, Chicago, IL; and
-
- Andreas Hochhaus
- Abteilung Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Thuringia, Germany
抄録
<jats:title>Key Points</jats:title> <jats:p>More patients with chronic myeloid leukemia in chronic phase achieve EMR on frontline nilotinib than imatinib. EMR failure on frontline nilotinib or imatinib predicts poor outcomes in patients with chronic myeloid leukemia in chronic phase.</jats:p>
収録刊行物
-
- Blood
-
Blood 123 (9), 1353-1360, 2014-02-27
American Society of Hematology